The Seasonal Affective Disorder Therapeutics market studied is anticipated to grow with a CAGR of nearly 6.3%, during the forecast period.

  • Certain factors that are driving the market growth include increasing prevalence of seasonal affective disorder and depression, growing R&D activities, and the rising number of treatment options.
  • Various antipsychotic medications are currently being used as a short-term treatment for bipolar disorder to control psychotic symptoms, such as hallucinations, delusions, or mania symptoms. These symptoms may occur during acute mania or severe depression. Some also treat bipolar depression, and several have demonstrated long-term value in preventing future episodes of mania or depression.
  • In people with bipolar disorder, antipsychotics are also used "off label" as sedatives, for insomnia, for anxiety, and/or for agitation. Often, they are taken with a mood-stabilizing drug and can decrease the symptoms of mania until mood stabilizers take full effect. Some medications seem to help stabilize moods on their own. The growing R&D activities are expected to fuel the market growth over the forecast period.



Key Market Trends

Bipolar Disorder Holds Significant Share in the Seasonal Affective Disorder Therapeutics Market

There is an increasing prevalence of bipolar disorder owing to the various risk factors, such as high stress, substance abuse, and others. According to the estimates of the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017 around 46 million people in the world had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar. The probability of men and women are being affected by bipolar disorder is similar. Hence, the rise in the cases of the disease and the increasing need to manage them effectively has led to the growth of the seasonal affective disorder therapeutics market.

North America Dominates the Seasonal Affective Disorder Therapeutics Market

North America is found to hold a major share for the seasonal affective disorder therapeutics market and is expected to show a similar trend over the forecast period, without significant fluctuations. Due to the increasing cases of bipolar disorder and the presence of better healthcare infrastructure, the market is expected to witness high growth over the forecast period.

According to the data published by the National Alliance on Mental Illness, around 1 in 5 adults in the United States experiences mental illness each year. Hospitalization is required for severe episodes of mania and depression to protect the patients from injuring themselves or others. According to the NIMH, bipolar disorder is characterized in part by manic symptoms that are so severe that the person needs immediate hospital care. There is a huge need to tackle mental disorder, as it is an increasing problem, and hence, the market is expected to grow during the forecast period.

Competitive Landscape

The global Seasonal Affective Disorder Therapeutics market is competitive and consists of a few major players. Companies like AbbVie Inc., Eli Lilly and Company, F. Hoffman-La Roche AG, GlaxoSmithKline plc., Mylan N.V., Novartis AG, Pfizer Inc., Teva Pharmaceuticals USA, Inc., among others, hold the substantial market share in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support